e-learning
resources
Virtual 2021
07.09.2021
Translational and other aspects of idiopathic interstitial pneumonia
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Real world data analysis indicates that pirfenidone may cause pellagra-like photosensitivity
T. Kuroita (Toyonaka, Japan), H. Yamamoto (Kyoto, Japan), N. Susai (Toyonaka, Japan), T. Yoshioka (Toyonaka, Japan), K. Kuronuma (Sapporo, Japan), S. Kaneko (Kyoto, Japan)
Source:
Virtual Congress 2021 – Translational and other aspects of idiopathic interstitial pneumonia
Session:
Translational and other aspects of idiopathic interstitial pneumonia
Session type:
E-poster
Number:
3280
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
T. Kuroita (Toyonaka, Japan), H. Yamamoto (Kyoto, Japan), N. Susai (Toyonaka, Japan), T. Yoshioka (Toyonaka, Japan), K. Kuronuma (Sapporo, Japan), S. Kaneko (Kyoto, Japan). Real world data analysis indicates that pirfenidone may cause pellagra-like photosensitivity. 3280
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Real world outcomes of Mepolizumab for severe asthma in Wales a retrospective analysis.
Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Year: 2020
Real world residual disease manifestations after 2-years anti-IL-5 treatment for severe asthma
Source: Virtual Congress 2020 – Severe asthma phenotypes and outcomes
Year: 2020
Real world idiopathic pulmonary fibrosis in the EMPIRE registry
Source: International Congress 2018 – The world of idiopathic pulmonary fibrosis (IPF): global registries
Year: 2018
Does timeliness of diagnosis influence survival and treatment response in idiopathic pulmonary fibrosis? Real- world results from the EMPIRE registry.
Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside
Year: 2017
Efficacy of azithromycin in a real world severe asthma cohort
Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments
Year: 2021
Real life experience with omalizumab and mepolizumab in severe asthma : do patient baseline features preclude effectiveness comparison ?
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Real life study showing the epidemiological profile and adherence to treatment of patients with severe allergic asthma in use of omalizumab in the past year.
Source: International Congress 2018 – Biomarkers for evaluating asthma
Year: 2018
Long term effect of doxycycline in asthma: a real world observation
Source: International Congress 2017 – Asthma: mechanisms and treatment
Year: 2017
Real world use of opioids in COPD patients
Source: Virtual Congress 2020 – Diagnosis and management of airways disease in primary care
Year: 2020
Real prevalence of severe asthma in developing countries – Is the diagnosis correct?
Source: Virtual Congress 2020 – Clinical parameters in severe asthma
Year: 2020
Real life benralizumab effect in patients with severe eosinophilic asthma after 16 weeks of observation
Source: Virtual Congress 2020 – Advances in asthma treatment
Year: 2020
Multivariate cluster analysis of immunopathological and clinical data from the U-BIOPRED severe asthma study: Preliminary results
Source: International Congress 2015 – New insights into lung disease pathogenesis
Year: 2015
Efficacy and safety of Mepolizumab in a real world severe asthma cohort.
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Real life application of basophil activation test: A real challenge for diagnosis and treatment monitoring of atopy-related diseases?
Source: Annual Congress 2012 - Aspects of clinical asthma
Year: 2012
Real current situation of management and for patient with asthma at community
Source: Annual Congress 2012 - Diagnostic insights and decision making in primary care
Year: 2012
Real world data from hospital episode statistics can be used to determine patients at risk of idiopathic pulmonary arterial hypertension
Source: International Congress 2018 – Clinical aspects of pulmonary hypertension
Year: 2018
Bleeding risk in IPF patients treated with different anticoagulants:Real world data from the European MultiPartner IPF Registry (EMPIRE)
Source: International Congress 2018 – The world of idiopathic pulmonary fibrosis (IPF): global registries
Year: 2018
Late Breaking Abstract - Six years experience of Pirfenidone treatment in IPF patients in Crete: Real life data
Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights
Year: 2017
Severe asthma exists despite suppressed tissue inflammation: findings of the U-BIOPRED study
Source: Eur Respir J 2016; 48: 1307-1319
Year: 2016
Efficacy of low dose pirfenidone in idiopathic pulmonary fibrosis: Real world experiencefrom a tertiary university hospital
Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept